[Asia Economy Reporter Chunhee Lee] Samsung Biologics is entering the contract manufacturing (CMO) of messenger ribonucleic acid (mRNA) vaccine active pharmaceutical ingredients (DS).
Samsung Biologics announced on the 25th that it has signed a CMO partnership for the active pharmaceutical ingredient of the COVID-19 mRNA vaccine candidate developed by Greenlight Biosciences. Samsung Biologics is currently establishing mRNA vaccine active pharmaceutical ingredient production facilities at its Incheon Songdo plant, aiming for cGMP (enhanced Current Good Manufacturing Practice) approval in the first half of next year.
Through this partnership, the two companies plan to accelerate Greenlight's COVID-19 mRNA vaccine clinical trials, commercial production, and local vaccine distribution, starting with low-income countries.
Greenlight Biosciences plans to begin Phase 1 clinical trials for the candidate substance in the first quarter of 2022 after finalizing clinical partners in research areas within Africa and obtaining regulatory approval. Earlier, in March, they announced the 'Global Vaccine Deployment Blueprint,' presenting a vision to produce billions of doses of COVID-19 mRNA vaccines annually to enhance equity in global vaccine distribution.
Andrei Zarur, CEO of Greenlight Biosciences, said, "We are pleased to collaborate with Samsung Biologics on the production of COVID vaccine clinical materials," adding, "Our vaccine clinical trials will open the way for not only developed countries but for everyone to have sufficient vaccine supply."
John Rim, President of Samsung Biologics, said, "We fully support Greenlight's vision to build a sustainable health environment for humanity in all regions worldwide," and added, "We will actively support Greenlight's efforts to expand global vaccine inoculation."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
